629 related articles for article (PubMed ID: 15853698)
21. QT alterations in psychopharmacology: proven candidates and suspects.
Alvarez PA; Pahissa J
Curr Drug Saf; 2010 Jan; 5(1):97-104. PubMed ID: 20210726
[TBL] [Abstract][Full Text] [Related]
22. Antipsychotic-related QTc prolongation, torsade de pointes and sudden death.
Haddad PM; Anderson IM
Drugs; 2002; 62(11):1649-71. PubMed ID: 12109926
[TBL] [Abstract][Full Text] [Related]
23. Beat-by-beat QT interval variability, but not QT prolongation per se, predicts drug-induced torsades de pointes in the anaesthetised methoxamine-sensitized rabbit.
Jacobson I; Carlsson L; Duker G
J Pharmacol Toxicol Methods; 2011; 63(1):40-6. PubMed ID: 20451633
[TBL] [Abstract][Full Text] [Related]
24. Drug-induced torsades de pointes: the evolving role of pharmacogenetics.
Fitzgerald PT; Ackerman MJ
Heart Rhythm; 2005 Nov; 2(2 Suppl):S30-7. PubMed ID: 16253929
[TBL] [Abstract][Full Text] [Related]
25. Further evidence of inherited long QT syndrome gene mutations in antiarrhythmic drug-associated torsades de pointes.
Lehtonen A; Fodstad H; Laitinen-Forsblom P; Toivonen L; Kontula K; Swan H
Heart Rhythm; 2007 May; 4(5):603-7. PubMed ID: 17467628
[TBL] [Abstract][Full Text] [Related]
26. Cellular mechanisms of Torsade de Pointes.
Poelzing S; Rosenbaum DS
Novartis Found Symp; 2005; 266():204-17; discussion 217-24. PubMed ID: 16050270
[TBL] [Abstract][Full Text] [Related]
27. Is gender a risk factor for adverse drug reactions? The example of drug-induced long QT syndrome.
Drici MD; Clément N
Drug Saf; 2001; 24(8):575-85. PubMed ID: 11480490
[TBL] [Abstract][Full Text] [Related]
28. [Evaluation of pro-arrhythmic risk of drugs due to QT interval prolongation by the HERG expression system].
Chachin M; Kurachi Y
Nihon Yakurigaku Zasshi; 2002 Jun; 119(6):345-51. PubMed ID: 12089906
[TBL] [Abstract][Full Text] [Related]
29. ILSI-HESI cardiovascular safety subcommittee initiative: evaluation of three non-clinical models of QT prolongation.
Hanson LA; Bass AS; Gintant G; Mittelstadt S; Rampe D; Thomas K
J Pharmacol Toxicol Methods; 2006; 54(2):116-29. PubMed ID: 16843688
[TBL] [Abstract][Full Text] [Related]
30. A pharmacokinetic-pharmacodynamic model for the quantitative prediction of dofetilide clinical QT prolongation from human ether-a-go-go-related gene current inhibition data.
Jonker DM; Kenna LA; Leishman D; Wallis R; Milligan PA; Jonsson EN
Clin Pharmacol Ther; 2005 Jun; 77(6):572-82. PubMed ID: 15961988
[TBL] [Abstract][Full Text] [Related]
31. Pharmacogenetic aspects of drug-induced torsade de pointes: potential tool for improving clinical drug development and prescribing.
Shah RR
Drug Saf; 2004; 27(3):145-72. PubMed ID: 14756578
[TBL] [Abstract][Full Text] [Related]
32. A history of the role of the hERG channel in cardiac risk assessment.
Rampe D; Brown AM
J Pharmacol Toxicol Methods; 2013; 68(1):13-22. PubMed ID: 23538024
[TBL] [Abstract][Full Text] [Related]
33. Allelic variants in long-QT disease genes in patients with drug-associated torsades de pointes.
Yang P; Kanki H; Drolet B; Yang T; Wei J; Viswanathan PC; Hohnloser SH; Shimizu W; Schwartz PJ; Stanton M; Murray KT; Norris K; George AL; Roden DM
Circulation; 2002 Apr; 105(16):1943-8. PubMed ID: 11997281
[TBL] [Abstract][Full Text] [Related]
34. Are hERG channel inhibition and QT interval prolongation all there is in drug-induced torsadogenesis? A review of emerging trends.
Hoffmann P; Warner B
J Pharmacol Toxicol Methods; 2006; 53(2):87-105. PubMed ID: 16289936
[TBL] [Abstract][Full Text] [Related]
35. Predicting drug-induced changes in QT interval and arrhythmias: QT-shortening drugs point to gaps in the ICHS7B Guidelines.
Lu HR; Vlaminckx E; Hermans AN; Rohrbacher J; Van Ammel K; Towart R; Pugsley M; Gallacher DJ
Br J Pharmacol; 2008 Aug; 154(7):1427-38. PubMed ID: 18493243
[TBL] [Abstract][Full Text] [Related]
36. Role of a KCNH2 polymorphism (R1047 L) in dofetilide-induced Torsades de Pointes.
Sun Z; Milos PM; Thompson JF; Lloyd DB; Mank-Seymour A; Richmond J; Cordes JS; Zhou J
J Mol Cell Cardiol; 2004 Nov; 37(5):1031-9. PubMed ID: 15522280
[TBL] [Abstract][Full Text] [Related]
37. Current concepts in the mechanisms and management of drug-induced QT prolongation and torsade de pointes.
Gupta A; Lawrence AT; Krishnan K; Kavinsky CJ; Trohman RG
Am Heart J; 2007 Jun; 153(6):891-9. PubMed ID: 17540188
[TBL] [Abstract][Full Text] [Related]
38. Drug-induced QT-interval prolongation and recurrent torsade de pointes in a child with heterotaxy syndrome and KCNE1 D85N polymorphism.
Lin L; Horigome H; Nishigami N; Ohno S; Horie M; Sumazaki R
J Electrocardiol; 2012; 45(6):770-3. PubMed ID: 22999324
[TBL] [Abstract][Full Text] [Related]
39. Drug-induced QT Interval Prolongation in the Intensive Care Unit.
Etchegoyen CV; Keller GA; Mrad S; Cheng S; Di Girolamo G
Curr Clin Pharmacol; 2017; 12(4):210-222. PubMed ID: 29473523
[TBL] [Abstract][Full Text] [Related]
40. Efficacy of ventricular pacing in the treatment of an arrhythmic storm associated with a congenital long QT mutation.
Aziz PF; Shah MJ
Congenit Heart Dis; 2013; 8(6):E165-7. PubMed ID: 23075154
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
